MedTrace Logo

Fatty Acid Oxidation Defects and Insulin Sensitivity

NCT02517307 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2024-01-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to learn more about what causes insulin resistance. It has been suggested that proper breakdown of fat into energy (oxidation) in the body is important to allow insulin to keep blood sugar in the normal range. The investigators want to know if having one of the fatty acid oxidation disorders could have an influence on insulin action. Fatty acid oxidation disorders are genetic disorders that inhibit one of the enzymes that converts fat into energy. The investigators will study both normal healthy people and people with a long-chain fatty acid oxidation disorder.

Conditions

  • Very Long-chain Acyl-CoA Dehydrogenase Deficiency
  • Trifunctional Protein Deficiency
  • Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency
  • Medium-chain Acyl-CoA Dehydrogenase Deficiency
  • Normal Volunteers
  • Carnitine Palmitoyltransferase II Deficiency, Myopathic

Interventions

DRUG

Intralipid/Heparin

Co-infusion of intralipid and heparin solutions during a hyperinsulinemic euglycemic clamp

DRUG

Glycerol/Saline

Co-infusion of a glycerol/saline solutions during a hyperinsulinemic euglycemic clamp

DRUG

Hyperinsulinemic euglycemic clamp

Infusion of insulin at at 40 mU/m2/min for 5 hours. Blood glucose will be monitored every 5 min during the insulin infusion and euglycemia will be maintained throughout the clamp by infusing 20% dextrose at a variable rate.

Sponsors & Collaborators

  • Oregon Health and Science University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2021-01-31
Completion
2021-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02517307 on ClinicalTrials.gov